MEDIA CENTER - 2013 - 2014

December 15, 2014
Translational Oncology publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper presents proof-of-efficacy data of ATX-101 in two immuno-competent, orthotopic rat models of superficial bladder cancer in combination with Mitomycin-C. Results from this study corroborate the therapeutic potential of the company's technology. A pdf copy of the published article is available here.

July 15, 2014
APIM Therapeutics is featured with an 1-page article in European Biotechnology, a publication presenting key biotechnology companies active in Europe. A pdf copy of the published article is available here.

July 1, 2014
BioMedResearch International publishes a scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper shows that impairing DNA damage responses in bladder cancer cells by using APIM Therapeutics's lead drug ATX-101, these cells become more sensitive to the action of chemotherapeutic drug bleomycin, used alone or together with photochemical internalization (PCI). A pdf copy of the publication is provided here.

February 28, 2014
A 2-page article devoted to the mechanism of action of APIM-peptides and its relevance to bladder cancer treatment was featured in the February 2014 edition of  Governments, Pan European Networks. Frequently contributed to by prestigious personalities of the European Union, this widely distributed magazine provides key interviews and articles in various technology fields including healthcare, energy and others. A pdf copy of the published article is available here.

November 11, 2013
APIM Therapeutics has completed a new financing round by existing investors Norsk Innovasjons-kapital III, Sarsia Seed, Birk Venture and Ro Invest. This financing will enable the company to continue development of ATX-101, its lead peptide drug, towards first-in-man clinical trials.

October 22, 2013
Aftenposten, a leading Norwegian newspaper, publishes supplement by the Oslo Cancer Cluster on the fight against cancer. The supplement features an article on APIM Therapeutics, see page 12. A copy of the supplement in pdf format can be downloaded here (in Norwegian). 

August 26, 2013
Finance Monthly, a global publication providing news, analysis and features on all the latest headlines within the financial sector in US, Europe and Asia nominates APIM Therapeutics's CEO Kostas Alevizopoulos for a 2013 CEO Award. A copy of the CEO Awards 2013 issue of Finance Monthly featuring an interview of K. Alevizopoulos is provided here (see page 15).

July 31, 2013
PLoS ONE publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper provides key data on the mechanism of action of ATX-101, the current company lead drug candidate, in various cellular models as well as proof-of-efficacy data in disease-relevant multiple myeloma ex vivo and in vivo models. Overall, ATX-101 shows strong efficacy in the absence of toxicity in agreement with the innovative therapeutic concept of the company. A pdf copy of the publication is provided here.

May 1, 2013
APIM Therapeutics will be presenting an abstract entitled "Increased efficacy of intravesical chemotherapy in an orthotopic rat bladder cancer model by targeting PCNA with the novel synthetic peptide drug ATX-101" at the Annual Meeting of the American Association of Urology held in San Diego in May 4-8, 2013.

May 28, 2013
APIM Therapeutics has been selected to present at the 10th European Partnering and Investment Conference (EPIC) held in London, UK in June 6, 2013. The conference brings together 250 - 300 delegates from the pharma, biotech, investor, CRO and service sectors.

May 1, 2013
APIM Therapeutics will be presenting an abstract entitled "Increased efficacy of intravesical chemotherapy in an orthotopic rat bladder cancer model by targeting PCNA with the novel synthetic peptide drug ATX-101" at the Annual Meeting of the American Association of Urology held in San Diego in May 4-8, 2013.

February 28, 2013
APIM Therapeutics will be presenting an abstract entitled "Targeting DNA repair mechanisms increases efficiency of intravesical chemotherapy in an orthotopic rat bladder cancer model" at the 28th Annual European Urology Association Meeting held in Milan in March 15-19, 2013.

February 27, 2013
APIM Therapeutics appoints Professor Per Uno Malmström (Department of Urology, Uppsala University, Sweden) at its scientific advisory board. Prof. Malmström, a recognized Key Opinion Leader in bladder cancer and Chairman of the Nordic Bladder Cancer Group, is expected to catalyze future clinical development of APIM Therepeutics's lead compound ATX-101 having significant experience in early phase I/II clinical trials for this indication. For more information, please see About Us.

February 18, 2013
APIM Therapeutics has been selected to present at the 6th ANNUAL EUROPEAN LIFE SCIENCE CEO FORUM PARTNERING & INVESTING in Biotech & Pharma Industry. The conference, which takes place in March 5-6, 2013 in Zurich, brings together together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.

January 23, 2013
Kostas Alevizopoulos, APIM Therapeutics's Chief Executive Officer gives an interview to Finance Monthly, an electronic journal focusing on private equity, acquisitions, funding and investments. A copy of the article is available at this address (see page 32).

Visit Media Center 2017
Visit Media Center 2015 & 2016
Visit Media Center 2012
Visit Media Center 2010 & 2011

To learn more the APIM-motif, ATX-101 and PCNA, please see attached the publications (given as pdf files):

1. Gilljam KM et al, 2009. Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol 186, pp645-654.

2. Müller R et al, 2013. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7).

3. Baglo Y et al, 2014. Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization. Biomed Res Int. 2014;2014:921296.

4. Gederaas OA et al, 2014. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014 Dec;7(6):812-23.

5. Olaisen C et al, 2014. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 2015 Jul;27(7):1478-87.

The following posters presented in TAT and AACR 2016 meetings provide latest efficacy data in bladder and breast cancer models as well as genomic and kinomic analysis conducted in these tumors:

6. Poster presented in the 14th International Congress on Targeted Anticancer Therapies.

7. Poster presented in the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer. 

For an excellent review discussing the druggability of PCNA and ATX-101:

8. Wang Shao-Chun, 2014. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014 Apr;35(4):178-186.

 

Trondheim

APIM Therapeutics AS is a spin-off from the Norwegian University of Science and Technology (NTNU).

Visit our About Us page to find out more.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see www.ntnu.no.

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit www.sarsiaseed.com to find out more.

About Birk Venture
Birk Venture is a Scandinavian venture company exclusively focusing on innovative life science companies. Visit www.birkventure.no to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit www.televenture.no to find out more.